Johnson & Johnson lost another bid to transfer 2,400 personal injury and wrongful death suits over allegedly contaminated talc powder products to Delaware federal court on Friday, when a judge found that the company failed to prove the case is "related to" its talc supplier's bankruptcy case.
The U.S. Department of Justice on Friday urged a D.C. federal judge to sign off on its settlement clearing CVS' purchase of Aetna, trying to rein in the scope of the court's review but facing resistance from the bench during oral arguments.
Endo Pharmaceuticals Inc. has agreed to pay $2.3 million to 18 states in a deal reached Friday, the same day the states hit the pharmaceutical company with a suit alleging it entered into a reverse-payment agreement to obstruct generic competition to Lidoderm, a pain relief patch.
An attorney defending Johnson & Johnson against claims its talcum powder caused mesothelioma pressed an environmental health expert on Friday to acknowledge research to the contrary, highlighting for a New Jersey jury asbestos studies by scientists and the company’s sophisticated quality control and asbestos detection methods.
The U.S. Department of Justice's newest indictment of a painkiller distributor and its executives strongly suggests that the agency has embarked on a calculated criminal crackdown after years of civil enforcement failed to ease the opioid epidemic.
The Seventh Circuit should reject attempts to cut the legs off a rule blocking indirect purchasers from suing a manufacturer for antitrust violations, the Washington Legal Foundation told the court, which is considering antitrust claims from buyers of syringes and catheters who think they were forced to pay too much.
Boston courthouses have been hopping as spring has turned to summer and high-profile white collar cases, the anticipated verdict in a landmark education and employment case, and a pair of cases dealing with courthouse immigration arrests have been filling up the Bay State's dockets. Here, Law360 highlights some of the most important cases to watch in the second half of 2019.
Venture capital-backed Radiology Partners, guided by Goodwin, said Friday it reached a $4 billion valuation following an investment from Starr Investment Holdings.
GlaxoSmithKline has renewed its bid to end multidistrict litigation in Massachusetts federal court over claims it didn’t warn customers about alleged birth defects resulting from its anti-nausea medication, saying a recent Supreme Court ruling opens the way for the judge to rule the claims are preempted by federal law.
Skadden Arps Slate Meagher & Flom LLP's John Beisner — recently tapped by Bayer AG to advise the company on the ongoing litigation over its weedkiller Roundup — talked with Law360 about what changes he's seen in mass tort proceedings, his most challenging cases and his reflections on the passing of the late Justice John Paul Stevens.
A New Jersey federal judge signed off Friday on a $6.2 million settlement in a proposed class action against Merck & Co. Inc. over gender discrimination claims from female former sales representatives, saying the agreement is set to benefit roughly 3,000 class members.
Sidley Austin LLP has hired former U.S. Rep. Peter Roskam, R-Ill., to join the firm's government strategies group after 25 years serving in both state and national government.
Zimmer Inc.’s quest to see its $254 million surgical tool patent infringement loss reviewed by the U.S. Supreme Court is “predicated on a strawman argument” and “completely misses the point” of the high court’s 2016 ruling relaxing the standard for enhanced patent damages, Stryker Corp. told the Supreme Court on Thursday.
A Kentucky travel agent who died of mesothelioma had a signature mix of talc and asbestos in her lung tissue traceable to talcum powder, according to evidence presented Thursday in an unusual joint trial against manufacturers Johnson & Johnson and Colgate-Palmolive.
Pfizer Inc. and its affiliates asked the U.S. Judicial Panel on Multidistrict Litigation Thursday to transfer a suit from West Virginia to Delaware, where 13 nearly identical federal complaints are pending that claim infringement of three drug patents central to a Pfizer breast cancer treatment.
A Philadelphia-area mergers and acquisitions adviser said Clark Hill PLC attorneys pressured him into accepting a settlement worth less than $1 million for a $63.5 million lawsuit, according to a professional malpractice claim filed Wednesday in a Pennsylvania state court.
CVS urged a Rhode Island federal judge not to certify classes of insured health plans claiming the company conspired with pharmacy benefits managers to overcharge them for generic drugs while secretly offering discounts to cash-paying customers, saying the fraud classes are undefinable.
An Arkansas woman sued Pfizer Inc. on Thursday, saying the company failed to warn U.S. customers that an arthritis drug can cause sepsis, resulting in the amputation of all four of her limbs, while European labels of the same drug contain such warnings.
The U.S. Tax Court would have been better served by a looser interpretation of the comparable uncontrolled transaction method in the Medtronic case, tax specialists who examined the use of different methods in transfer pricing cases said Thursday.
Bayer Corp. has been hit with a lawsuit in Illinois state court claiming the company misrepresented the safety of its Essure permanent birth control device and hid its serious and potentially life-threatening risks in women.
Five companies’ shares began trading on U.S. exchanges Thursday after the companies, led by a Danish biotechnology firm, priced initial public offerings that together raised nearly $1.1 billion.
Potts Law Firm and other Texas firms accused of improperly pocketing excessive attorney fees from roughly 1,450 pelvic mesh victims have asked a New Jersey federal court to toss a proposed class action against them, arguing the plaintiff didn't actually "sustain any damages."
Drug distributor Miami-Luken Inc. flooded rural towns with painkillers to profit off an epidemic of opioid addiction, the U.S. Department of Justice said in an indictment unsealed Thursday that targets the company and two of its executives.
A group of pharmaceutical companies is urging the Seventh Circuit not to revive a suit by Medical Mutual of Ohio that accused them of running a conspiracy to hide the harmful effects of testosterone supplements, saying the insurer never showed how it relied on their alleged misrepresentations.
The Second Circuit on Thursday affirmed the conviction of notorious former pharmaceutical executive Martin Shkreli on securities fraud and conspiracy charges, saying there was no error in the jury instructions at his trial.
Most written advocacy to the Bureau of Competition is of an extremely high quality, but sometimes we notice that there’s some room for improvement, says Daniel Francis, an associate director at the Federal Trade Commission's Bureau of Competition.
Following recent rule changes, U.S. International Trade Commission determinations and decisions by the Federal Circuit, proposed respondents may be able to prevent or limit the scope of ITC Section 337 investigations if they act quickly using various types of preinstitution submissions, says Michael Doane of Miles & Stockbridge.
Rothschild Barry's John Coffey, who joined Justice John Paul Stevens' law firm in 1965, shares what it was like to watch Justice Stevens practice law, mentor younger lawyers and land a malfunctioning plane.
This month, China's new regulations governing the management of human genetic resources came into effect, bringing stronger enforcement measures and much heavier liabilities that will require many companies, medical and research institutions, and universities to upgrade their compliance systems accordingly, say attorneys at Tian Yuan.
So that health and life sciences companies can better determine whether the information they collect is subject to the California Consumer Privacy Act, Jason Linder and Libby Jelinek of Irell & Manella address the scope of certain CCPA exemptions and identify the main areas of ambiguity.
The U.S. Supreme Court's decision in Kisor v. Wilkie, weakening Auer deference, gives courts more authority to challenge agency decisions — even those concerning very technical regulations, as many of the U.S. Food and Drug Administration's do, say attorneys at Axinn.
While there is discussion in some quarters about new regulations on commercial legal finance, the hands-off approach taken by the majority of courts and legislatures is an implicit recognition that it is already sufficiently regulated, says Danielle Cutrona of Burford Capital.
A recent Iowa Supreme Court ruling concerning a local airport commission's authority to condemn a structure declared safe by the Federal Aviation Administration presents many of the same preemption questions that will play out in opioid litigation, says Richard Dean of Tucker Ellis.
The administrative record is very important to federal agency litigation — as showcased in last month's U.S. Supreme Court decision concerning the addition of a citizenship question to the 2020 census — yet there is no set of consistent principles to guide agencies in compiling these official records, say attorneys at WilmerHale.
Since 32 of the 67 decisions issued by the U.S. Supreme Court during its October term cite dictionaries, it’s worth reviewing the opinions to learn which dictionaries the justices consulted and how they used them, say Bruce Wessel and Brian Weissenberg of Irell & Manella.
Although the rate of employment for law school graduates — which had been falling steadily — saw a small increase over the last year, other factors, such as fewer graduates overall and potential future job growth stagnation, temper the good news for those pursuing law degrees, say Tiffane Cochran and Tyler Grimm of AccessLex Institute.
The approach to patents practiced by fashion brands needs to evolve as technology’s integration into fashion becomes more frequent and complex, says Barry Lewin of Gottlieb Rackman.
Chinese investment in the U.S. biotech industry is attracting increased government oversight, as evidenced by the Committee on Foreign Investment in the United States blocking several such transactions in the last 16 months. Two important proposed rules could materially affect the industry further, say attorneys at Morgan Lewis.
If passed, the Affordable Prescriptions for Patients Act will limit the number of patents that can be raised in litigation under the Biologics Price Competition and Innovation Act, with significant repercussions for biosimilar applicants deciding whether to engage in a patent dance, say attorneys at Paul Hastings.
Leveraging the collective strengths of a diverse workforce is not only the right thing to do, it’s a strategic imperative for any successful firm or business, says Louise Pentland, executive vice president and chief business affairs and legal officer of PayPal.